Global Antimicrobial resistance Platform for ONE Burden Estimates (GAP-ONE)
Network coordinator: Luigia Scudeller, IRCCS Policlinic San Matteo, Italy
Summary of the Network
Relevance of antimicrobial resistance (AMR) costs is amply acknowledged by many global and international institutions and organisations. Even so, current figures fail to capture the full health and economic burden caused by AMR. Most current estimates are based only on the human health perspective, with data from high-income countries, and a fully One Health integrated approach to cost estimates is lacking: What are the entire shadow costs attributable to AMR, worldwide and across the diverse, interconnected domains of human health, animal health and the environment, of the One Health areas? If available, these estimates would constitute a powerful benchmark for advocating in favour of global action against AMR, for evaluating cost-effectiveness of interventions aiming at tackling AMR, and even for identifying opportunities for reallocating resources to research and development of new antimicrobial therapies.
The GAP-ONE Network aims to create a virtual research environment able to:
- Involve all stakeholders into a Network that will provide an opportunity for participants from different disciplines to interconnect more fully and effectively.
- Identify all the data elements required to build a reliable tool for estimating resource waste due to AMR worldwide, not only in human health but also integrating veterinary and environmental data, within a One Health approach.
- Provide a framework to assess data quality.
- Devise a strategy for sharing currently available information.
The GAP-ONE Network includes human and veterinary clinicians, human and veterinary microbiologists, experts in antimicrobial resistance burden, food safety, health-economics, and international law, as well as infection control experts, clinical epidemiologists, statisticians, and health information librarians. The Network will also involve additional stakeholders, such as patient organisations, drug and diagnostics manufacturers, social science experts, behavioural change experts, health authorities, and governmental agencies. We will aim at including all stakeholders included in the “AMR stakeholder mapping” ReAct Europe – Action on Antibiotic Resistance – A global mapping of stakeholders working with antimicrobial resistance. We will meet at least three times during the project: one face-to-face workshop and at least two teleconference meetings.
Expected outputs of the Network
- Mapping of stakeholders
- Online global platform (including taxonomy and quality control) to collect, share, connect and disseminate data and info on AMR costs
- Common framework to assess data quality
- Open access scientific publications (1-2) in peer-reviewed journals
- Communication activities (dedicated website, social media, quarterly newsletter, national meetings, international conferences
- Physical meeting (month 8)
- Final scientific report
- Final grant report
JPIAMR priority topics: Environment, Surveillance